Bolt Biotherapeutics, Inc. (BOLT)
|Net Income (ttm)||n/a|
|Trading Day||June 11|
|Day's Range||16.15 - 16.72|
|52-Week Range||16.00 - 43.07|
Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001...
REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...
Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properti...
Bolt's first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study Bolt's first-in...
REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the tar...
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising –
Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.
Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Pu...
REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of...
REDWOOD CITY, Calif.-- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced...
Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Bolt Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
We are a clinical-stage immuno-oncology company developing tumor-targeted therapies. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems by activating and recruiting myeloid cells, thereby re-programming the tumor microenvironment to invoke an adaptive immune response. We believe that this process leads to the development of systemic immunological memory achi... [Read more...]
|IPO Date |
Feb 5, 2021
Randall C. Schatzman, Ph.D.
|Stock Exchange |
|Ticker Symbol |
In 2020, BOLT's revenue was $231,000, an increase of 7.44% compared to the previous year's $215,000. Losses were -$60.73 million, 99.2% more than in 2019.